| abstract |
The new use of non-receptor tyrosine kinase c-Ab1 specific inhibitors alone or in combination with cisplatin or cyclophosphamide in preparing antitumor medicaments and / or auxiliary antitumor medicaments. Experiments prove that non-receptor tyrosine kinase c-Ab1 specific inhibitors can inhibit the activity of c-Ab1 kinase to lead the denaturation aggregation and lysosome degradation of Gal3 and to lower the Gal3 protein level in the tumor cells obviously, so as to kill tumor cells in autophagic apoptosis. |